http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Exact Sciences (EXAS) to combine with Genomic Health (GHDX) for $72/share in cash and stock transaction valued at $2.8 billion
-
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
-
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
-
Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
-
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
-
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit,
-
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
-
Genomic Health to Present at the Jefferies 2019 Healthcare Conference
-
Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
-
Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
-
Genomic Health (GHDX) Says Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score Tes
-
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
-
Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
-
Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
-
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
-
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
-
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
-
Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
-
Genomic Health (GHDX) NICE Expands Recommendation for Oncotype DX Breast Recurrence Score Test to More Patients with Early-Stage Breast Cancer
-
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
-
Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or R
-
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
-
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the
-
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
-
Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
-
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
-
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
-
Genomic Health (GHDX) Says Medicare Established Final Local Coverage Determination for Use of the Oncotype DX AR-V7 Nucleus Detect Test
-
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective Decembe
-
Genomic Health (GHDX) Reports Multiple Studies Reinforcing Value of Oncotype DX Tests in Guiding Treatment for Breast & Prostate Cancer Patients
-
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
-
New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
-
New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS™) Test
-
Epic Sciences Announces Completion of $52 Million Series E Financing
-
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
-
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
-
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
-
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
-
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
-
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
-
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage B
-
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
-
Genomic Health (GHDX) Highlights New Data Reinforcing Positive Impact of Oncotype DX Genomic Prostate Score
-
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score™ Test in Guiding Treatment Decisions
-
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
-
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
-
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
-
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic